pharma · Becker Muscular Dystrophy · Muscular Dystrophies · EWTX
Edgewise Therapeutics
Edgewise Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1715 38th St., Boulder, CO 80301, US
- Founded
- 2017
- Employees
- 154
- Programs
- 15
- Drugs
- 3
- Patents
- 7
Edgewise Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Edgewise Therapeutics.
Edgewise Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
EDG-5506, EDG-5506
Edgewise Therapeutics
Becker Muscular Dystrophy
1 trial -
EDG-7500
Edgewise Therapeutics
Hypertrophic Cardiomyopathy
1 trial -
Sevasemten
Edgewise Therapeutics
Becker Muscular Dystrophy
2 trials -
Sevasemten 10 mg
Edgewise Therapeutics
Becker Muscular Dystrophy
1 trial -
Sevasemten Dose 1
Edgewise Therapeutics
Duchenne Muscular Dystrophy
2 trials
Frequently asked questions
How many clinical projects does Edgewise Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.